/* font effect */

bootstrap-js-components

Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPharm) is established in 2006. The institutes aim to be a Biotechnology's Centers of Excellence by exploiting megadiversity of Malaysian natural resources for the development of new drugs. IPharm therefore has a mission to conduct world-class R&D to accelerate the discovery, development and commercialization of pharmaceutical and nutraceutical products. For years, IPharm has established its capacity by developing the infrastructure and human resource. An integrated multi-disciplinary drug discovery team and related technologies including molecular biology, medicinal chemistry synthesis, molecular modeling, automated high-throughput screening, animal pharmacology, pharmacokinetics, drug metabolism, and formulation studies have been develop during these years. For the coming years, IPharm will take steps to position as an integrated institute for applied research and development of new pharmaceuticals and nutraceuticals. Some of the big projects that have been taken by IPharm are:

  1. Developing National Natural Products Repository (MyNature 50000)
  2. IPharm Pilot Plant: Evidence Based Product Development Centre
  3. IPharm Animal Research Facility: National Integrated Preclinical Toxicity Research Centre with International Accreditation Program

We are now ready to roll out our operations and our approach will continue to be to work with all stakeholders and leverage the well established pharmaceutical and healthcare researches, resources and industries. We have demonstrated success and most importantly, research institutes, industry partners, the government and the community are ready and waiting for us to fill this very important role. I hope that you will take some time to explore this site to learn more about the IPharm. I hope that you will be able to visit us. We are here to answer any questions you may have about our services.

Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPharm) was established on 29th November 2006 under the Ministry of Science, Technology and Innovation in order to spearhead this initiative by delivering world-class R&D to accelerate the discovery, development and commercialization of pharmaceutical and nutraceutical products. IPHARM is a multidisciplinary research instutes aim to be a Biotechnology's Centers of Excellence by exploiting megadiversity of our natural resources for the development of new drugs. IPharm therefore has a mission to conduct world-class R&D to accelerate the discovery, development and commercialization of pharmaceutical and nutraceutical products.

 

Tun Dato' Sri Haji Abdullah bin Haji Ahmad during BioMalaysia Conference on 28 April 2005 at Putrajaya International Conference Centre(PICC. This policy, endorsed by the Malaysian Cabinet on 20 April 2015 emphasises on the development of three core areas of biotechnology, namely the agriculture, healthcare and industry. Under NBP's Healthcare Biotechnology thrust, the government aspires to get benefit from country's enviable wealth in natural resources especially in drug discovery and development. Concurrently, the potential of bio-generics market is also recognized as an important area in healthcare biotechnology.

 

Realizing the challenges in developing the healthcare biotechnology is competitive, the Cabinet endorsed the proposal to establish a centre of excellence. This historical decision marks the birth of the Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPharm). The establishment of the IPharm was approved by the Biotechnology Implementation Council on 7 September 2006 and approved by the Cabinet on 26 November 2006 with two other institutions namely Agro Biotechnology Institute (ABI) and the Malaysian Genome Institute (MGI) under the Ministry of Science, Technology and Innovation. IPharm research facility, previously located within Universiti Sains Malaysia (USM) campus in Pulau Pinang, was relocated to the interim research facility namely SAINS@USM Complex located at Bukit Jambul, Pulau Pinang in 2008.

 

Then, in 2011 IPharm has its own building complex strategically located in Halaman Bukit Gambir, Pulau Pinang with area of 10 acres. IPharm was established as a centre of excellence to spearhead the NBP thrusts by delivering world class R&D in order to accelerate the discovery, development and commercialisation of pharmaceutical and nutraceutical products as well as to build the nation's skilled human resources in Healthcare Biotechnology. In 1 March 2014, all the three institutes established under NBP (IPharm, ABI and MGI) had been transformed and incorporated as National Institutes of Biotechnology Malaysia (NIBM), a not for profit government organisation operating as Company Limited by Guarantee (CLG). This transformation is a move forward for IPharm in ensuring its vision of becoming a Center of Excellence in research and development in healthcare biotechnology become reality. By this transformation, it is hoped that IPharm will be more independent, surge forward with more proactive and dynamic and focus on revenue generation process which include in the production of products and services.

In 1 March 2014, all the three institutes established under NBP (IPharm, ABI and MGI) had been transformed and incorporated as National Institutes of Biotechnology Malaysia (NIBM), a not for profit government organisation operating as Company Limited by Guarantee (CLG). This transformation is a move forward for IPharm in ensuring its vision of becoming a Center of Excellence in research and development in healthcare biotechnology become reality. By this transformation, it is hoped that IPharm will be more independent, surge forward with more proactive and dynamic and focus on revenue generation process which include in the production of products and services.

Mission Vission
To implement R & D, develop human capital & expertise,
Strengthen strategic collaboration in global healthcare biotechnology,
Leading to commercialization.
A center of excellence for commercialization driven R & D in healthcare biotechnology

The National Biotechnology Division (BIOTEK) under the Ministry of Science, Technology and Innovation (MOSTI)has been given the responsibility to lead the national agenda through R&D, technology development and promotion of biotechnology programs. In 2002, three interim laboratories - Genomic & Molecular Biology; Agro-Biotechnology; and Pharmaceuticals & Nutraceuticals were established to provide research infrastructure for the 8th Malaysia Plan for National Biotechnology Agenda led by the Biotechnology Cooperative Centres (BCCs).In 2005, these laboratories were inaugurated as National Biotechnology Institutes to lead, coordinate and implement the national biotechnology agenda through activities research, development, innovation and commercialization (RDIC). The three National Biotechnology Institutes are:

 Malaysia Agro-Biotechnology Institute (ABI)
ABI undertakes Research, Development and Commercialization projects related to agro-biotechnology in cooperation with various universities, research institutions and industry players.

 Malaysia Institute of Pharmaceuticals and Nutraceuticals (IPharm)
IPHARM is a multidisciplinary research institute that focuses its efforts on drug discovery and development. Through high impact R&D activities and strategic alliances with world-class research institutions, IPHARM aims to develop new pharmaceuticals and nutraceuticals with commercialization potential.

 Malaysia Genome Institute (MGI) Genome Malaysia 
Genom Malaysia is a network-based not-for-profit organization undertaking basic and translational research aimed at the generation of new intellectual properties and technologies for economic development via large-scale collaborative projects in Comparative Genomics and Genetics, Structural and Synthetic Biology, Computational and Systems Biology, Metabolic Engineering.

   

In 2011, the institutes were restructured and placed under an autonomous organization called the National Institutes of Biotechnology Malaysia (NIBM). While the three institutes focus on high quality and market driven R&D and innovations, NIBM key role is to support and spearhead the commercialization of the R&D activities at the institutes based on industry requirements. NIBM was eventually registered on 27 January 2012 as a Company Limited by Guarantee (CLG) not for profit under the purview of MOSTI and began operations on 1st March 2012.

The pursuit of commercialization activities at NIBM is driven by the following key components:

  • Market-driven & lab to market R&D
  • Industry partnership
  • Talent & expertise training
  • Repository natural bio-resources
  • Shared core facilities
  • International collaboration
  • // text_effect.